Roche Holding AG (SWX:RO)
Switzerland
· Delayed Price · Currency is CHF 278.80
+1.80 (0.65%)
May 20, 2025, 5:30 PM CET
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
604.32K CHF
Profits / Employee
80.17K CHF
Market Cap
208.62B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 103,249 | -356 | -0.34% |
| Dec 31, 2023 | 103,605 | -8 | -0.01% |
| Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
| Dec 31, 2021 | 100,920 | -545 | -0.54% |
| Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Roche Holding AG | 103,249 |
| Novartis AG | 75,883 |
| Lonza Group AG | 18,944 |
| Alcon | 25,599 |
| Galderma Group AG | 6,545 |
| Straumann Holding AG | 11,815 |
| Sonova Holding AG | 18,151 |
| Sandoz Group AG | 22,049 |
Roche Holding AG News
- 5 days ago - Trump's drug pricing order puts Roche's $50 billion U.S. investment plans at risk - Fast Company
- 5 days ago - Is It Time to Invest in Europe? - Kiplinger
- 5 days ago - Roche receives FDA approval for the VENTANA MET (SP44) RxDx Assay as the first companion diagnostic to identify non-squamous non-small cell lung cancer patients eligible for treatment with Emrelis - GlobeNewsWire
- 5 days ago - Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsight - Benzinga
- 6 days ago - Roche reportedly warns Trump’s executive order can risk its U.S. investments - Seeking Alpha
- 6 days ago - Trump's drug pricing order threatens Roche's $50 billion US investment plans, company says - Reuters
- 6 days ago - Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17% - Benzinga
- 7 days ago - Ten-Year APHINITY Data Show Genentech's Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer - Business Wire